Zoetis Earnings Call Transcripts
Fiscal Year 2026
-
Revenue growth is projected at 3%-5% for 2026, led by parasiticides and supported by strong livestock performance. Long-acting therapies and new franchises in renal, oncology, and cardiology are expected to drive future growth, while AI and field team restructuring enhance operational efficiency.
-
2025 saw strong growth, led by livestock and international diversification, despite U.S. consumer pressures and competitive launches. Triple combination parasiticides and dermatology remain key growth drivers, with a robust pipeline targeting major unmet needs. Capital allocation focuses on investment, M&A, and shareholder returns.
-
Pet health spending remains resilient, with growth in emergency and preventive care, while innovative products like Trio and Key Derm drive expansion through high satisfaction and compliance. The pipeline is robust, targeting kidney disease and OA pain, and capital allocation prioritizes R&D, M&A, and shareholder returns.
-
Solid 2025 results and prudent 2026 guidance reflect resilience amid competition and macro headwinds. Calendar reporting will shift to a synchronized year in 2026, with recasted financials for comparability. Product differentiation, innovation pipeline, and omni-channel strategy support continued growth.
-
Animal health is set for strong growth, with robust sectoral tailwinds and a market expected to nearly double in a decade. Innovation, a diverse pipeline, and disciplined execution underpin sustained revenue and margin expansion, while strategic capital allocation and global reach support long-term leadership.
Fiscal Year 2025
-
Delivered 6% organic revenue and 7% adjusted net income growth in 2025, led by international and livestock segments. 2026 guidance targets 3%-5% organic revenue growth amid ongoing macro and competitive pressures, with continued investment in innovation and disciplined capital allocation.
-
R&D efficiency and a robust innovation engine are driving a diverse pipeline, with major product launches planned annually through 2030. Librela is stabilizing and expected to return to growth in 2026, while competitive dynamics remain manageable due to strong product differentiation and market expansion strategies.
-
Animal health is poised for significant growth, with a robust pipeline targeting chronic diseases, oncology, and long-acting therapies. Advanced R&D, AI integration, and global scale position the company for sustained innovation, market leadership, and strong financial performance.
-
Q3 2025 saw 4% organic revenue growth and 9% adjusted net income growth, with strong international and livestock performance offsetting U.S. companion animal softness. Guidance was narrowed, with stabilization expected in OA pain and continued above-market livestock growth.
-
Resilient industry trends and strong macro drivers support robust growth in animal health, with innovation and commercial execution fueling outperformance. The company targets 6.5%-8% revenue growth in 2025, driven by core franchises, pipeline launches, and expanding alternative channels. Margin expansion is expected as the business mix shifts toward higher-margin companion animal products.
-
Delivered 8% organic revenue and 10% adjusted net income growth, led by double-digit gains in key franchises and strong international performance. Raised full-year guidance for both revenue and net income, while addressing competitive and tariff headwinds.
-
A global animal health leader is leveraging innovation, customer connectivity, and a diversified portfolio to outpace industry growth. Major pipeline opportunities in chronic kidney disease, oncology, and cardiology are expected to drive future expansion, while disciplined financial management supports margin and EPS growth.
-
Mitigation strategies for tariffs are in place, with strong U.S. manufacturing and ongoing investments. Revenue growth is robust, led by double-digit gains in dermatology and parasiticides, while alternative channels rapidly expand. New long-acting products are set to drive future growth.
-
Guidance was revised due to tariffs, but organic growth remains strong, supported by a diversified supply chain and robust mitigation strategies. Librela’s U.S. uptake is slower than abroad, but education and new product launches are expected to drive growth. Sustained innovation, channel diversification, and the aging pet population underpin a positive long-term outlook.
-
The meeting covered board elections, executive compensation, and a shareholder proposal to ease requirements for calling special meetings, which the board opposed. Strong 2024 financial results and strategic growth initiatives were highlighted, with innovation and omnichannel strategies driving performance.
-
Q1 2025 saw 9% organic revenue growth and 6% adjusted net income growth, led by strong international and companion animal performance. Full-year guidance was maintained for revenue and updated for net income due to tariffs, with continued focus on innovation and operational excellence.
-
Achieved record growth in 2024, driven by companion animal and OA pain franchises, with strong prospects for continued double-digit growth in 2025. Pipeline innovation, market expansion, and resilience to macroeconomic pressures support a positive outlook.
-
Strong 2024 results and double-digit growth across key franchises set the stage for continued momentum in 2025. Librela's finalized label and high clinic penetration support further adoption, while a robust pipeline and global expansion drive long-term growth. Margin expansion and disciplined capital allocation remain priorities.
-
Strong 2024 performance was driven by innovation, market expansion, and robust growth in companion animal and livestock segments. The pipeline promises annual major launches, including long-acting therapies and new market entries in renal, oncology, and cardiology, with significant market expansion expected.
Fiscal Year 2024
-
Delivered 11% operational revenue growth and 15% adjusted net income growth in 2024, led by strong performance in companion animal and dermatology franchises. 2025 guidance calls for 6%-8% organic operational growth, with continued investment in innovation and shareholder returns.
-
Secular trends and innovation are driving above-market growth in companion animal health, with robust expansion in dermatology and parasiticides. New launches like Librela and Apoquel Chewable are performing well, and the pipeline remains strong across multiple therapeutic areas.
-
Double-digit growth continued in Q3, led by strong performance in dermatology, parasiticides, and OA pain franchises. Price and volume contributed equally to growth, with strategic divestitures and product launches positioning for sustained expansion into 2025.
-
Q3 2024 saw 14% operational revenue growth and 15% operational adjusted net income growth, led by strong performance in companion animal and livestock segments. Key franchises like Librela, Simparica Trio, and dermatology products drove results, with raised full-year guidance and continued above-market growth expected into 2025.
-
Strong innovation and disciplined capital allocation drive above-guidance growth, led by companion animal products and rapid adoption of new launches like Librela. Channel shifts, robust pipeline, and margin expansion initiatives position the business for sustained outperformance.
-
Q2 2024 saw 11% operational revenue growth and 18% operational Adjusted Net Income growth, driven by strong performance in companion animal and livestock portfolios. Full-year guidance was raised, a $6B share repurchase program was announced, and robust demand continues despite macroeconomic headwinds.
-
The company continues to outperform the resilient animal health industry, driven by innovation, customer engagement, and a diversified portfolio. Q1 2024 saw strong growth in companion animal products, especially dermatology and OA pain, leading to raised full-year guidance.